Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
F 144.61 -0.37% -0.53
ABBV closed down 0.37 percent on Wednesday, February 8, 2023, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Feb 9
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -0.37%
NR7 Range Contraction -0.28%
Inside Day Range Contraction -0.28%
Oversold Stochastic Weakness -0.28%
Slingshot Bearish Bearish Swing Setup -0.41%
Gapped Up Strength -0.41%
Oversold Stochastic Weakness -0.41%
Oversold Stochastic Weakness -0.16%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 7 hours ago
Rose Above 10 DMA about 12 hours ago
10 DMA Resistance about 12 hours ago
Rose Above Previous Day's High about 12 hours ago
Possible NR7 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AbbVie Inc. Description

AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Acid Autoimmune Disease Pharmaceutical Products Organic Compounds Chemical Compounds Prostate Cancer Distribution Center Cardiology Respiratory Diseases Thyroid Cholesterol Anesthesia Chloroarenes Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Testosterone Triglyceride Hyperparathyroidism Niacin Advanced Prostate Cancer Carbidopa Secondary Hyperparathyroidism Anesthesia Product Celiac Celiac Disease Exocrine Pancreatic Insufficiency Hypothyroidism Research Based Biopharmaceutical Testosterone Replacement Therapy

Is ABBV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 174.2532
52 Week Low 132.8273
Average Volume 5,199,202
200-Day Moving Average 147.79
50-Day Moving Average 155.99
20-Day Moving Average 148.22
10-Day Moving Average 145.85
Average True Range 2.47
RSI 30.56
ADX 34.99
+DI 13.49
-DI 29.62
Chandelier Exit (Long, 3 ATRs) 157.31
Chandelier Exit (Short, 3 ATRs) 150.84
Upper Bollinger Bands 154.43
Lower Bollinger Band 142.01
Percent B (%b) 0.21
BandWidth 8.38
MACD Line -3.20
MACD Signal Line -3.12
MACD Histogram -0.0831
Fundamentals Value
Market Cap 255.3 Billion
Num Shares 1.77 Billion
EPS 4.57
Price-to-Earnings (P/E) Ratio 31.63
Price-to-Sales 4.13
Price-to-Book 12.13
PEG Ratio 1.28
Dividend 5.20
Dividend Yield 3.60%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 147.42
Resistance 3 (R3) 147.68 147.02 146.95
Resistance 2 (R2) 147.02 146.30 146.88 146.79
Resistance 1 (R1) 145.81 145.86 145.48 145.55 146.64
Pivot Point 145.15 145.15 144.98 145.01 145.15
Support 1 (S1) 143.94 144.43 143.61 143.68 142.58
Support 2 (S2) 143.28 143.99 143.14 142.43
Support 3 (S3) 142.07 143.28 142.27
Support 4 (S4) 141.81